News

Filter by:
By year:
Reset
  • Publication

BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today

  • Publication
  • Stargardt

Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models